Alyeska Investment Group
FULC icon

Alyeska Investment Group’s Fulcrum Therapeutics FULC Stock Holding History

Alyeska Investment Group’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,328,449
Closed -$10.2M – 713
2026
Q1 		$10.2M Buy
+1,328,449
New +$12.3M 0.03% 398
2024
Q3 		– Sell
-202,148
Closed -$1.25M – 590
2024
Q2 		$1.25M Hold
202,148
– – 0.01% 449
2024
Q1 		$1.91M Hold
202,148
– – 0.01% 379
2023
Q4 		$1.36M Hold
202,148
– – 0.01% 391
2023
Q3 		$898K Hold
202,148
– – 0.01% 425
2023
Q2 		$667K Buy
202,148
+50,000
+33% +$147K 0.01% 479
2023
Q1 		$434K Buy
+152,148
New +$1.36M ﹤0.01% 419
2021
Q1 		– Sell
-452,797
Closed -$5.3M – 767
2020
Q4 		$5.3M Buy
452,797
+244,040
+117% +$2.76M 0.07% 261
2020
Q3 		$1.66M Buy
+208,757
New +$2.51M 0.03% 368
2020
Q1 		– Sell
-75,551
Closed -$1.26M – 404
2019
Q4 		$1.26M Sell
75,551
-74,714
-50% -$714K 0.02% 319
2019
Q3 		$998K Buy
+150,265
New +$1.66M 0.01% 324

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Alyeska Investment Group's FULC Position: Q2 2026 in Review

Alyeska Investment Group sold out of Fulcrum Therapeutics (FULC) in Q2 2026, closing a stake of 1,328,449 shares — an estimated $10.2M sold.

Alyeska Investment Group first reported a position in FULC in Q3 2019 and held it in 11 quarters. The position peaked at $10.2M in Q1 2026. 154 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • Alyeska Investment Group reported no remaining Fulcrum Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Alyeska Investment Group sold 1,328,449 Fulcrum Therapeutics shares in Q2 2026, an estimated $10.2M.
  • Alyeska Investment Group first reported a position in Fulcrum Therapeutics in Q3 2019 and held it in 11 quarters.
  • Alyeska Investment Group's Fulcrum Therapeutics position peaked at $10.2M in Q1 2026.
  • 154 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.